Psoriatic News and Research

RSS

XenoPort initiates XP23829 Phase 2 clinical trial in patients with psoriasis

XenoPort, Inc. announced today that it has initiated a Phase 2 clinical trial of XP23829, its proprietary investigational next-generation fumaric acid product candidate. The trial is a multi-center, randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of XP23829 as a potential treatment of patients with moderate-to-severe chronic plaque-type psoriasis.

23 Jun 2014

One-third of PsA patients not receiving adalimumab doses to achieve optimal clinical benefit

Data presented today at the European League Against Rheumatism Annual Congress showed that a significant number of patients with psoriatic arthritis (PsA) were not receiving doses of the tumour necrosis factor-alpha (TNFα) inhibitor adalimumab necessary to achieve optimal clinical benefit.

12 Jun 2014

Celgene: OTEZLA phase III study for psoriatic arthritis meets primary endpoint

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced results of additional analyses from the phase III clinical trials of OTEZLA, the Company's oral, selective inhibitor of phosphodiesterase 4 (PDE4).

11 Jun 2014

Researchers find standard heart disease risk assessment tools for rheumatoid arthritis patients

Rheumatoid arthritis patients overall are twice as likely as the average person to develop heart problems. Pinpointing which rheumatoid arthritis patients need stepped-up heart disease prevention efforts has been a challenge; research by Mayo Clinic and others has found that standard heart disease risk assessment tools may underrate the danger a particular person faces.

11 Jun 2014

AbbVie's ALIGN study underscores patients’ attitudes and adherence toward TNF inhibitors

AbbVie today announced results from its multi-country ALIGN study, which shows that across six chronic immune-mediated inflammatory diseases (IMIDs), adherence to treatment was generally higher in patients being treated with TNF inhibitors compared to patients treated with conventional therapy.

11 Jun 2014

Covagen begins COVA322 Phase Ib/IIa study to treat patients with rheumatoid and psoriatic arthritis

Covagen today announced it has initiated a Phase Ib/IIa study with COVA322, a bispecific TNF/IL-17A inhibitor.

6 May 2014

NPF researchers to get access to Corrona’s psoriatic arthritis registry to improve patient outcomes

To improve treatment decisions and patient outcomes for psoriatic arthritis (PsA)—a chronic inflammatory arthritis that affects the joints and tendons—the National Psoriasis Foundation and Corrona, LLC are collaborating to give NPF-affiliated researchers access to Corrona’s psoriatic arthritis registry, which is the largest psoriatic arthritis registry in the world.

25 Apr 2014

Johnson & Johnson's sales increase 3.5% to $18.1 billion in first quarter 2014

Johnson & Johnson today announced sales of $18.1 billion for the first quarter of 2014, an increase of 3.5% as compared to the first quarter of 2013. Operational results increased 5.3% and the negative impact of currency was 1.8%. Domestic sales increased 2.2%. International sales increased 4.5%, reflecting operational growth of 7.9% and a negative currency impact of 3.4%.

15 Apr 2014

Leading experts discuss the economic burden of psoriasis and psoriatic arthritis on patient and society

A panel of leading experts representing different sectors of the health care community met to discuss the significant and underestimated burden psoriasis and psoriatic arthritis have on patients, the health care system and economy, and the impact medical innovation has on reducing these burdens.

1 Apr 2014

With three weeks to go, Obama administration pulls out all the stops in sign up efforts

News outlets report on the creative outreach efforts, including those geared to moms, young people and Latinos, to increase the number of newly insured people before March 31. Even prison inmates are signing up.

11 Mar 2014

UK waiting times for RA and PsA patients: an interview with Dr Marwan Bukhari, Consultant Rheumatologist at the University Hospitals of Morecambe Bay NHS Foundation Trust

Research shows that in cases of inflammatory joint disease, the earlier you catch the disease and suppress the immune system, the less likely a patient is to develop damaging and ongoing, chronic inflammation.

10 Mar 2014

Researchers discover novel treatments for psoriasis that are likely to cause fewer side effects

Almost ten years ago, the group led by Erwin Wagner, currently at the Spanish National Cancer Research Centre (CNIO), developed genetically modified mice showing symptoms very reminiscent to psoriasis.

28 Feb 2014

Alvogen launches Inflectra into Central and Eastern Europe

Alvogen, the multinational pharmaceuticals company, today announced the launch of Inflectra (Infliximab) into Central and Eastern Europe. Inflectra, Europe's first biosimilar monoclonal antibody (mAb) therapy that has been approved for the treatment of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis, Crohn's disease (CD), ulcerative colitis (UC), psoriatic arthritis (PsA) and psoriasis.

13 Feb 2014

Psoriasis registry: an interview with Dr. Andrew D. Robertson, Chief Scientific and Medical Officer, National Psoriasis Foundation

Psoriasis is the most common autoimmune disease in the US, affecting 2 to 3% of all Americans. What causes psoriasis in any one individual will stem from a mixture of their genetic background and their environment.

4 Feb 2014

NPF, CORRONA to create first psoriasis registry to improve treatments and patient outcomes

To advance understanding of psoriasis—the most common autoimmune disease in the country, affecting up to 7.5 million Americans—and help scientists and clinicians improve treatments and patient outcomes, the National Psoriasis Foundation and the Consortium of Rheumatology Researchers of North America, Inc. will create the first psoriasis registry co-developed and co-administered by a nonprofit.

10 Jan 2014

Novel combination anti-psoriasis therapy targets genetic abnormalities in deeper layers of the skin

A novel combination anti-psoriasis therapy has potential for superior and longer-lasting therapeutic effects than current topical treatments by targeting genetic abnormalities in deeper layers of the skin. This research is being presented at the 2013 American Association of Pharmaceutical Scientists Annual Meeting and Exposition, the world's largest pharmaceutical sciences meeting, in San Antonio, Nov. 10-14.

15 Nov 2013

Women taking immunosuppressive medications during pregnancy do not put their babies at risk

Women with chronic autoimmune diseases who take immunosuppressive medications during their first trimester of pregnancy are not putting their babies at significantly increased risk of adverse outcomes, according to a Vanderbilt study released online by the journal Arthritis and Rheumatism.

11 Nov 2013

Researchers link species of intestinal bacteria to onset of rheumatoid arthritis

Researchers have linked a species of intestinal bacteria known as Prevotella copri to the onset of rheumatoid arthritis, the first demonstration in humans that the chronic inflammatory joint disease may be mediated in part by specific intestinal bacteria.

6 Nov 2013

IFPA brings attention to the need for improving treatment, care for psoriasis

Today, on World Psoriasis Day, the International Federation of Psoriasis Associations, IFPA, brings attention to the need for improving the availability of treatment and care for psoriasis - a disease that affects more than 125 million people all over the world.

29 Oct 2013

Phase 3 study shows STELARA inhibits structural damage in patients with active psoriatic arthritis

New findings from two integrated Phase 3 Janssen Research & Development, LLC (Janssen)-sponsored studies showed treatment with STELARA- (ustekinumab) resulted in significantly greater inhibition of structural damage in patients with active psoriatic arthritis compared with placebo.

29 Oct 2013

Psoriatic News and Research

XenoPort initiates XP23829 Phase 2 clinical trial in patients with psoriasis

One-third of PsA patients not receiving adalimumab doses to achieve optimal clinical benefit

Celgene: OTEZLA phase III study for psoriatic arthritis meets primary endpoint

Researchers find standard heart disease risk assessment tools for rheumatoid arthritis patients

AbbVie's ALIGN study underscores patients’ attitudes and adherence toward TNF inhibitors

Covagen begins COVA322 Phase Ib/IIa study to treat patients with rheumatoid and psoriatic arthritis

NPF researchers to get access to Corrona’s psoriatic arthritis registry to improve patient outcomes

Johnson & Johnson's sales increase 3.5% to $18.1 billion in first quarter 2014

Leading experts discuss the economic burden of psoriasis and psoriatic arthritis on patient and society

With three weeks to go, Obama administration pulls out all the stops in sign up efforts

UK waiting times for RA and PsA patients: an interview with Dr Marwan Bukhari, Consultant Rheumatologist at the University Hospitals of Morecambe Bay NHS Foundation Trust

Researchers discover novel treatments for psoriasis that are likely to cause fewer side effects

Alvogen launches Inflectra into Central and Eastern Europe

Psoriasis registry: an interview with Dr. Andrew D. Robertson, Chief Scientific and Medical Officer, National Psoriasis Foundation

NPF, CORRONA to create first psoriasis registry to improve treatments and patient outcomes

Novel combination anti-psoriasis therapy targets genetic abnormalities in deeper layers of the skin

Women taking immunosuppressive medications during pregnancy do not put their babies at risk

Researchers link species of intestinal bacteria to onset of rheumatoid arthritis

IFPA brings attention to the need for improving treatment, care for psoriasis

Phase 3 study shows STELARA inhibits structural damage in patients with active psoriatic arthritis

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News